×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
CSTL – castle biosciences, inc. - common stock (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
CSTL
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/13
02:18 pm
cstl
Castle Biosciences (CSTL): Valuation Check After Expert Panel Endorses DecisionDx-Melanoma Test [Yahoo! Finance]
Neutral
Report
Castle Biosciences (CSTL): Valuation Check After Expert Panel Endorses DecisionDx-Melanoma Test [Yahoo! Finance]
12/12
08:06 am
cstl
Castle Biosciences (NASDAQ:CSTL) had its price target raised by analysts at BTIG Research from $38.00 to $50.00. They now have a "buy" rating on the stock.
Low
Report
Castle Biosciences (NASDAQ:CSTL) had its price target raised by analysts at BTIG Research from $38.00 to $50.00. They now have a "buy" rating on the stock.
12/12
07:39 am
cstl
Systematic Review and Meta-Analysis Confirms TissueCypher® Outperforms Traditional Pathology or Clinical Factors Alone to Identify Patients at Increased Risk of Developing Esophageal Cancer [Yahoo! Finance]
Low
Report
Systematic Review and Meta-Analysis Confirms TissueCypher® Outperforms Traditional Pathology or Clinical Factors Alone to Identify Patients at Increased Risk of Developing Esophageal Cancer [Yahoo! Finance]
12/12
07:00 am
cstl
Systematic Review and Meta-Analysis Confirms TissueCypher® Outperforms Traditional Pathology or Clinical Factors Alone to Identify Patients at Increased Risk of Developing Esophageal Cancer
Low
Report
Systematic Review and Meta-Analysis Confirms TissueCypher® Outperforms Traditional Pathology or Clinical Factors Alone to Identify Patients at Increased Risk of Developing Esophageal Cancer
12/9
07:00 am
cstl
Expert Melanoma Panel Recommends Castle Biosciences’ DecisionDx®-Melanoma as a Best-Practice Tool for Managing Patients with Melanoma
Low
Report
Expert Melanoma Panel Recommends Castle Biosciences’ DecisionDx®-Melanoma as a Best-Practice Tool for Managing Patients with Melanoma
11/21
07:04 pm
cstl
Does New Melanoma Data Redefine the Bull Case for Castle Biosciences' DecisionDx Platform (CSTL)? [Yahoo! Finance]
Medium
Report
Does New Melanoma Data Redefine the Bull Case for Castle Biosciences' DecisionDx Platform (CSTL)? [Yahoo! Finance]
11/20
01:33 pm
cstl
Castle Biosciences (NASDAQ:CSTL) had its "sell (d)" rating reaffirmed by analysts at Weiss Ratings.
Low
Report
Castle Biosciences (NASDAQ:CSTL) had its "sell (d)" rating reaffirmed by analysts at Weiss Ratings.
11/17
09:13 am
cstl
Castle Biosciences Earns a Houston Chronicle Top Workplaces Award for the Fifth Consecutive Year [Yahoo! Finance]
Low
Report
Castle Biosciences Earns a Houston Chronicle Top Workplaces Award for the Fifth Consecutive Year [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
11/3/2025
04:07 pm
cstl
castle biosciences, inc. - common stock
BEAT
Report
21.7%
castle biosciences, inc. - common stock
8/4/2025
04:05 pm
cstl
castle biosciences, inc. - common stock
BEAT
Report
32.8%
castle biosciences, inc. - common stock
5/5/2025
04:06 pm
cstl
castle biosciences, inc. - common stock
MISS
Report
-10.7%
castle biosciences, inc. - common stock
2/27/2025
04:05 pm
cstl
castle biosciences, inc. - common stock
BEAT
Report
-14.2%
castle biosciences, inc. - common stock
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
12/11
06:49 pm
cstl
Form 4 CASTLE BIOSCIENCES INC For: Dec 09 Filed by: MAETZOLD DEREK J
Low
Report
Form 4 CASTLE BIOSCIENCES INC For: Dec 09 Filed by: MAETZOLD DEREK J
12/11
06:48 pm
cstl
Form 4 CASTLE BIOSCIENCES INC For: Dec 09 Filed by: Oelschlager Kristen M
Low
Report
Form 4 CASTLE BIOSCIENCES INC For: Dec 09 Filed by: Oelschlager Kristen M
12/11
06:46 pm
cstl
Form 4 CASTLE BIOSCIENCES INC For: Dec 09 Filed by: Stokes Frank
Low
Report
Form 4 CASTLE BIOSCIENCES INC For: Dec 09 Filed by: Stokes Frank
12/11
06:45 pm
cstl
Form 4 CASTLE BIOSCIENCES INC For: Dec 09 Filed by: Juvenal Tobin W
Low
Report
Form 4 CASTLE BIOSCIENCES INC For: Dec 09 Filed by: Juvenal Tobin W
12/11
04:30 pm
cstl
Form 144 CASTLE BIOSCIENCES INC Filed by: Juvenal Tobin W
Low
Report
Form 144 CASTLE BIOSCIENCES INC Filed by: Juvenal Tobin W
12/11
04:07 pm
cstl
Form 144 CASTLE BIOSCIENCES INC Filed by: Stokes Frank
Low
Report
Form 144 CASTLE BIOSCIENCES INC Filed by: Stokes Frank
12/8
04:29 pm
cstl
Form 4 CASTLE BIOSCIENCES INC For: Dec 04 Filed by: MAETZOLD DEREK J
Low
Report
Form 4 CASTLE BIOSCIENCES INC For: Dec 04 Filed by: MAETZOLD DEREK J
12/4
04:08 pm
cstl
Form 4 CASTLE BIOSCIENCES INC For: Dec 02 Filed by: MAETZOLD DEREK J
Low
Report
Form 4 CASTLE BIOSCIENCES INC For: Dec 02 Filed by: MAETZOLD DEREK J
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
11/11
Q3/2019 9/30/2019 EPS 0.050 ZacksConsensus -0.310 ActVsEst 0.360 - Beat
19.6%
3/16 Castle Biosciences (NASDAQ: CSTL) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $27.00 price target on the stock. 18.9%
8/22 Castle Biosciences to Release Second Quarter 2019 Financial Results and Host Conference Call on Tuesday, September 3, 2019 14.1%
4/6 Castle Biosciences to Present at the 19th Annual Needham Virtual Healthcare Conference 13.4%
10/29 Castle Biosciences Presents Clinical Validation Study for its Cutaneous Squamous Cell Carcinoma Prognostic Test at the American Society for Dermatologic Surgery (ASDS) 2019 Annual Meeting 11.0%
7/31 Form 4 CASTLE BIOSCIENCES INC For: Jul 29 Filed by: Cook Joseph C. III 10.9%
12/19 Form 8-K CASTLE BIOSCIENCES INC For: Dec 13 8.6%
10/31 Study Results Confirm Newly Developed Nomogram Using Castle Biosciences’ DecisionDx-Melanoma Test Improves Assessment of Melanoma Patient Risk 8.4%
10/29 Castle Biosciences (NASDAQ: CSTL) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. 8.3%
1/3 Castle Biosciences (NASDAQ: CSTL) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 7.6%
3/16 Castle Biosciences (NASDAQ: CSTL) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $27.00 price target on the stock. 18.9%
8/22 Castle Biosciences to Release Second Quarter 2019 Financial Results and Host Conference Call on Tuesday, September 3, 2019 14.1%
4/6 Castle Biosciences to Present at the 19th Annual Needham Virtual Healthcare Conference 13.4%
10/29 Castle Biosciences Presents Clinical Validation Study for its Cutaneous Squamous Cell Carcinoma Prognostic Test at the American Society for Dermatologic Surgery (ASDS) 2019 Annual Meeting 11.0%
7/31 Form 4 CASTLE BIOSCIENCES INC For: Jul 29 Filed by: Cook Joseph C. III 10.9%
12/19 Form 8-K CASTLE BIOSCIENCES INC For: Dec 13 8.6%
10/31 Study Results Confirm Newly Developed Nomogram Using Castle Biosciences’ DecisionDx-Melanoma Test Improves Assessment of Melanoma Patient Risk 8.4%
10/29 Castle Biosciences (NASDAQ: CSTL) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. 8.3%
1/3 Castle Biosciences (NASDAQ: CSTL) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 7.6%
TOP News Decliners
3/11
Castle Biosciences (NASDAQ: CSTL) had its price target raised by analysts at Robert W. Baird from $37.00 to $38.00. They now have an "outperform" rating on the stock.
-12.7%
10/21 Castle Biosciences (NASDAQ: CSTL) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. -11.8%
9/6 Castle Biosciences (NASDAQ: CSTL) was given a new $33.00 price target on by analysts at Leerink Swann. They now have a "buy" rating on the stock. -11.5%
3/11 Castle Biosciences Inc (CSTL) Q4 2019 Earnings Call Transcript [The Motley Fool] -11.5%
2/25 Castle Biosciences to Release Fourth Quarter and Full Year 2019 Financial Results and Host Conference Call on Tuesday, March 10, 2020 -9.4%
2/21 Form 4 CASTLE BIOSCIENCES INC For: Feb 19 Filed by: HealthQuest Venture Management, L.L.C. -7.4%
1/13 Castle Biosciences (NASDAQ: CSTL) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $38.00 price target on the stock. -7.0%
9/3 Form 8-K CASTLE BIOSCIENCES INC For: Sep 03 -6.9%
10/18 Castle Biosciences Presents Data at the ASDP 56th Annual Meeting Supporting DecisionDx-Melanoma Test’s Ability to Identify T1 Melanoma Patients at Low Risk for a Positive Sentinel Lymph Node -5.7%
7/29 Form S-8 CASTLE BIOSCIENCES INC -5.3%
10/21 Castle Biosciences (NASDAQ: CSTL) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. -11.8%
9/6 Castle Biosciences (NASDAQ: CSTL) was given a new $33.00 price target on by analysts at Leerink Swann. They now have a "buy" rating on the stock. -11.5%
3/11 Castle Biosciences Inc (CSTL) Q4 2019 Earnings Call Transcript [The Motley Fool] -11.5%
2/25 Castle Biosciences to Release Fourth Quarter and Full Year 2019 Financial Results and Host Conference Call on Tuesday, March 10, 2020 -9.4%
2/21 Form 4 CASTLE BIOSCIENCES INC For: Feb 19 Filed by: HealthQuest Venture Management, L.L.C. -7.4%
1/13 Castle Biosciences (NASDAQ: CSTL) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $38.00 price target on the stock. -7.0%
9/3 Form 8-K CASTLE BIOSCIENCES INC For: Sep 03 -6.9%
10/18 Castle Biosciences Presents Data at the ASDP 56th Annual Meeting Supporting DecisionDx-Melanoma Test’s Ability to Identify T1 Melanoma Patients at Low Risk for a Positive Sentinel Lymph Node -5.7%
7/29 Form S-8 CASTLE BIOSCIENCES INC -5.3%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: